Cormac Sheridan
Freelance science journalist. I write about what works in biotech - & what doesn't. Write for @NatureBiotech & one half of Smith & Sheridan on Biotech podcast
Articles
-
Jan 13, 2025 |
nature.com | Cormac Sheridan
From corn to bananas, farmers stand to gain from cultivating edited crops that are resilient and sustainable, paired with precision insecticides and microbe engineering. But reaching those with the greatest need remains a challenge.
-
Nov 22, 2024 |
informaconnect.com | Cormac Sheridan
ReproNovo made its debut appearance at BIO-Europe. This new reproductive medicine company is moving quickly. Founded just three years ago, it has already built a pipeline comprising two assets, which are in development across three disease areas. RPN-001 will enter a phase 2 trial in male infertility, while RPN-002 will enter two phase 2 trials - to aid embryo implantation in women undergoing in vitro fertilization (IVF) and to treat symptoms of adenomyosis.
-
Nov 14, 2024 |
informaconnect.com | Cormac Sheridan
As the curtain fell on BIO-Europe 2024, and attendees turned for home, the re-election of Donald Trump as U.S. president loomed large. The ordinary business of biotechnology will doubtless continue during his second term – regardless of their political affiliation, people will always get sick and need access to innovative healthcare.
-
Nov 14, 2024 |
informaconnect.com | Cormac Sheridan
I have a dream was the Abba-themed title for a panel, at BIO-Europe 2024,hosted by TVM Capital Life Science, which considered the future of artificial intelligence (AI) in drug discovery. The same song also mentions a belief in angels, but the panel participants grounded their views in a more hard-headed consideration of what AI can – and cannot do – to advance drug discovery and development.
-
Nov 13, 2024 |
informaconnect.com | Cormac Sheridan
China has quickly moved from being essentially a generics supplier to becoming one of the world’s top three biotech R&D centers. Although its first embrace of biotech innovation was based on a ‘fast-follow’ model, addressing clinical targets identified and validated elsewhere, the country is now an originator, focused on novel products and technologies that are globally competitive. That is reflected in the rapid growth in dealmaking involving Chinese assets.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 1K
- Tweets
- 6K
- DMs Open
- No
RT @Kit_Yates_Maths: 🚨I promised I'd say more on the Royal Society and Elon Musk, so here it is. 🚨 I've resigned my position as Associate…
Agriculture is threatened by & contributes to climate change. My latest in @naturebiotech takes a look at precision breeding in agriculture - to boost productivity & resilience & reduce its environmental damage. https://t.co/r8RbH4fhXy #biotech #agbio #plantfood
RT @FinucaneCentre: Malachy Clerkin: After 27 years of being ignored by British government, some good news at last for Seán Brown’s family…